跳至主要内容
临床试验/NCT06512831
NCT06512831已完成不适用

Isoniazid Prophylaxis Based on Risk Factors of Tuberculosis in Living Kidney Transplantation Recipients: A Retrospective Cohort Study

West China Hospital1 个研究点 分布在 1 个国家目标入组 1,348 人开始时间: 2023年6月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
1,348
试验地点
1
主要终点
The incidence of post-transplant active TB

研究概览

简要总结

Tuberculosis (TB) is a major and severe opportunistic infection among solid organ transplant recipients. Chemoprophylaxis is advised for those with latent tuberculosis infection (LTBI). However, the effectiveness of an isoniazid (INH) prophylactic approach based on TB risk factors, without relying on tuberculin skin test (TST) or interferon-gamma release assay (IGRA), remains uncertain. Therefore, the investigators conducted this retrospective study to evaluate the safety and efficacy of a 6-month INH prophylaxis regimen guided by TB risk factors in kidney transplant recipients.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • living-donor kidney transplant recipients
  • receiving standard triad immunosuppressive regimen

排除标准

  • active TB infection
  • multiorgan transplantation
  • liver cirrhosis
  • malignancy history in the donor and recipient
  • human immunodeficiency virus infection
  • those who had received a nine-month course of INH.

研究组 & 干预措施

TB Risk factors with INH group (R-INH)

Experimental

干预措施: Isoniazid (Drug)

结局指标

主要结局

The incidence of post-transplant active TB

时间窗: from transplant to post-transplant for up to 5 years

次要结局

  • The incidence of side effects of INH(Within 6 months of INH regimen)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Tao Lin

Professor Tao Lin

West China Hospital

研究点 (1)

Loading locations...

相似试验